Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2014 May;7(3):401-8.
doi: 10.1161/CIRCHEARTFAILURE.113.000840. Epub 2014 Apr 15.

Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial

Robert J Mentz  1 , Stephen J Greene  1 , Andrew P Ambrosy  1 , Muthiah Vaduganathan  1 , Haris P Subacius  1 , Karl Swedberg  1 , Aldo P Maggioni  1 , Savina Nodari  1 , Piotr Ponikowski  1 , Stefan D Anker  1 , Javed Butler  1 , Mihai Gheorghiade  2
Affiliations
Comparative Study

Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial

Robert J Mentz et al. Circ Heart Fail. 2014 May.

Abstract

Background: Anemia has been associated with worse outcomes in patients with chronic heart failure (HF). We aimed to characterize the clinical profile and postdischarge outcomes of hospitalized HF patients with anemia at admission or discharge.

Methods and results: An analysis was performed on 3731 (90%) of 4133 hospitalized HF patients with ejection fraction ≤40% enrolled in the Efficacy of Vasopressin Antagonist in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial with baseline hemoglobin data, comparing the clinical characteristics and outcomes (all-cause mortality and cardiovascular mortality or HF hospitalization) of patients with and without anemia (hemoglobin <12 g/dL for women and <13 g/dL for men) on admission or discharge/day 7. Overall, 1277 patients (34%) were anemic at baseline, which persisted through discharge in 73% and resolved in 27%; 6% of patients without baseline anemia developed anemia by discharge or day 7. Patients with anemia were older, with lower blood pressure, and higher creatinine and natriuretic peptide levels compared with those without anemia (all P<0.05). After risk adjustment, anemia at discharge, but not admission, was independently associated with increased all-cause mortality (hazard ratio, 1.30; 95% confidence interval, 1.05-1.60; P=0.015; and hazard ratio, 0.94; 95% confidence interval, 0.76-1.15; P=0.53, respectively) and cardiovascular mortality plus HF hospitalization early postdischarge (≤100 days; hazard ratio 1.73; 95% confidence interval, 1.37-2.18; P<0.001; and hazard ratio, 0.92; 95% confidence interval, 0.73-1.16; P=0.47, respectively). Neither baseline nor discharge anemia was associated with long-term cardiovascular mortality plus HF hospitalization (>100 days) on adjusted analysis (both P>0.1).

Conclusions: Among hospitalized HF patients with reduced ejection fraction, modest anemia at discharge but not baseline was associated with increased all-cause mortality and short-term cardiovascular mortality plus HF hospitalization.

Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00071331.

Keywords: anemia; heart failure; hemoglobin; hospitalization.

PubMed Disclaimer

Conflict of interest statement

Disclosures

Dr Swedberg received research grants from AstraZeneca, Servier, and Amgen; honoraria from AstraZeneca, Otsuka, Servier, and Amgen; and is consultant to Cytokinetics, Servier, and Novartis. Dr Maggioni received honoraria from Otsuka. Dr Gheorghiade is consultant to Abbott Laboratories, Astellas, AstraZeneca, Bayer Schering PharmaAG, CorThera Inc, Cytokinetics Inc, DebioPharm S.A., Errekappa Terapeutici, GlaxoSmithKline, JNJ, Medtronic, Novartis Pharma AG, Otsuka, Sigma Tau, Solvay Pharmaceuticals, and Pericor Therapeutics. Dr Butler is consultant to Amgen. The other authors report no conflicts.

Figures

Figure 1
Figure 1
Analytic cohort. EVEREST indicates Efficacy of Vasopressin Antagonist in Heart Failure Outcome Study with Tolvaptan; and Hgb, hemoglobin.
Figure 2
Figure 2
Hemoglobin values during the follow-up period in those with and without discharge anemia.
Figure 3
Figure 3
Kaplan–Meier survival curves for (A) all-cause mortality and (B) cardiovascular mortality or heart failute (HF) hospitalization in patients with HF based on whether anemia was (1) absent, (2) developed during hospitalization, (3) present at baseline but resolved by discharge or d 7, or (4) persisted from admission through discharge or d 7. Log-rank P value <0.001 for both figures.
See this image and copyright information in PMC

References

    1. Anand IS. Anemia and chronic heart failure implications and treatment options. J Am Coll Cardiol. 2008;52:501–511. - PubMed
    1. Lindenfeld J. Prevalence of anemia and effects on mortality in patients with heart failure. Am Heart J. 2005;149:391–401. - PubMed
    1. Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, van der Meer P. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol. 2008;52:818–827. - PubMed
    1. Tang YD, Katz SD. The prevalence of anemia in chronic heart failure and its impact on the clinical outcomes. Heart Fail Rev. 2008;13:387–392. - PubMed
    1. van der Meer P, Groenveld HF, Januzzi JL, Jr, van Veldhuisen DJ. Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Heart. 2009;95:1309–1314. - PubMed

Publication types

MeSH terms

Associated data